Literature DB >> 20974823

Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.

Michael J McConnell1, Juan Domínguez-Herrera, Younes Smani, Rafael López-Rojas, Fernando Docobo-Pérez, Jerónimo Pachón.   

Abstract

Acinetobacter baumannii causes pneumonias, bacteremias, and skin and soft tissue infections, primarily in the hospitalized setting. The incidence of infections caused by A. baumannii has increased dramatically over the last 30 years, while at the same time the treatment of these infections has been complicated by the emergence of antibiotic-resistant strains. Despite these trends, no vaccines or antibody-based therapies have been developed for the prevention of A. baumannii infection. In this study, an outer membrane complex vaccine consisting of multiple surface antigens from the bacterial membrane of A. baumannii was developed and tested in a murine sepsis model. Immunization elicited humoral and cellular responses that were able to reduce postinfection bacterial loads, reduce postinfection proinflammatory cytokine levels in serum, and protect mice from infection with human clinical isolates of A. baumannii. A single administration of the vaccine was able to elicit protective immunity in as few as 6 days postimmunization. In addition, vaccine antiserum was used successfully to therapeutically rescue naïve mice with established infection. These results indicate that prophylactic vaccination and antibody-based therapies based on an outer membrane complex vaccine may be viable approaches to preventing the morbidity and mortality caused by this pathogen.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974823      PMCID: PMC3019872          DOI: 10.1128/IAI.00741-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

2.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 3.  Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii.

Authors:  Pak-Leung Ho; Vincent Chi-Chung Cheng; Chung-Ming Chu
Journal:  Chest       Date:  2009-10       Impact factor: 9.410

4.  Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients.

Authors:  J L García-Garmendia; C Ortiz-Leyba; J Garnacho-Montero; F J Jiménez-Jiménez; J Monterrubio-Villar; M Gili-Miner
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

5.  Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Authors:  H Wisplinghoff; M B Edmond; M A Pfaller; R N Jones; R P Wenzel; H Seifert
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

6.  Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.

Authors:  I J Jang; I S Kim; W J Park; K S Yoo; D S Yim; H K Kim; S G Shin; W H Chang; N G Lee; S B Jung; D H Ahn; Y J Cho; B Y Ahn; Y Lee; Y G Kim; S W Nam; H S Kim
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

7.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

8.  Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific.

Authors:  Catherine W M Ong; David C B Lye; Kay Leong Khoo; Gerald Seng Wee Chua; Siang Fei Yeoh; Yee Sin Leo; Paul Ananth Tambyah; Arlene Christine Chua
Journal:  Respirology       Date:  2009-11       Impact factor: 6.424

Review 9.  Proteomic analysis of a fraction enriched in cell envelope proteins of Acinetobacter baumannii.

Authors:  Sara Martí; Javier Sánchez-Céspedes; Eliandre Oliveira; David Bellido; Ernest Giralt; Jordi Vila
Journal:  Proteomics       Date:  2006-04       Impact factor: 3.984

Review 10.  Vaccination and passive immunisation against Staphylococcus aureus.

Authors:  Adam C Schaffer; Jean C Lee
Journal:  Int J Antimicrob Agents       Date:  2008-08-30       Impact factor: 5.283

View more
  53 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

2.  Current advances and challenges in the development of Acinetobacter vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Healthcare-associated infections: potential for prevention through vaccination.

Authors:  E David G McIntosh
Journal:  Ther Adv Vaccines Immunother       Date:  2018-03-14

4.  Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology.

Authors:  Ming-Hsien Chiang; Wang-Chou Sung; Shu-Pei Lien; Ying-Zih Chen; Annie Fei-yun Lo; Jui-Hsin Huang; Shu-Chen Kuo; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.

Authors:  Shun Xin Wang-Lin; Ruth Olson; Janet M Beanan; Ulrike MacDonald; Joseph P Balthasar; Thomas A Russo
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

6.  Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii.

Authors:  Leticia V Bentancor; Ana Camacho-Peiro; Cagla Bozkurt-Guzel; Gerald B Pier; Tomás Maira-Litrán
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

7.  Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections.

Authors:  Leticia V Bentancor; Abhisek Routray; Cagla Bozkurt-Guzel; Ana Camacho-Peiro; Gerald B Pier; Tomás Maira-Litrán
Journal:  Infect Immun       Date:  2012-07-23       Impact factor: 3.441

8.  Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection.

Authors:  Greg Harris; Bruce E Holbein; Hongyan Zhou; H Howard Xu; Wangxue Chen
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

9.  Induction of human plasmablasts during infection with antibiotic-resistant nosocomial bacteria.

Authors:  Victor I Band; Chris Ibegbu; Surinder Pal Kaur; Stephanie M Cagle; Ronald Trible; Crystal L Jones; Yun F Wang; Colleen S Kraft; Susan M Ray; Jens Wrammert; David S Weiss
Journal:  J Antimicrob Chemother       Date:  2014-02-28       Impact factor: 5.790

10.  The Nod1, Nod2, and Rip2 axis contributes to host immune defense against intracellular Acinetobacter baumannii infection.

Authors:  Pradeep Bist; Neha Dikshit; Tse Hsien Koh; Alessandra Mortellaro; Thuan Tong Tan; Bindu Sukumaran
Journal:  Infect Immun       Date:  2013-12-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.